CONMED Corp. 10-Q Summary: Quarter Ended June 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended June 30, 2001. CONMED Corporation is a medical technology company specializing in instruments and implants for arthroscopic sports medicine, powered surgical instruments, and advanced medical devices including RF electrosurgery systems and ECG electrodes. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 2001 | 6 Months Ended June 2001 |
|---|---|---|
| Net Sales | $104,171 | $210,080 |
| Net Income | $5,734 | $11,737 |
| Diluted EPS | $0.37 | $0.75 |
| Gross Margin % | 52.0% | 52.6% |
| Operating Cash Flow | N/A | $17,569 |
| Total Debt (Current + Long-term) | $367,698 | $367,698 |
| Cash and Equivalents | $924 | $924 |
| Working Capital | $116,024 | $116,024 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.4% for the quarter and 4.7% for the six-month period compared to the prior year. Orthopaedic sales grew 5.9% (quarter) and 4.3% (six months). Minimally Invasive Surgery (MIS) sales surged 87.5% (quarter) and 89.7% (six months), largely driven by the November 2000 Imagyn acquisition.
- Profitability: Net income rose 63.1% for the quarter and 7.4% for the six-month period. Gross margins improved to 52.0% (quarter) and 52.6% (six months) due to higher volume in high-margin orthopaedic products.
- Expenses: Selling and administrative expenses increased slightly in absolute terms but decreased as a percentage of sales (32.6% vs. 34.0% in Q2 2000). The prior year Q2 included a $1.5 million nonrecurring severance charge; excluding this, S&A expenses were consistent year-over-year.
- Interest Expense: Interest expense declined to $7.8 million (quarter) and $16.2 million (six months) due to lower total borrowings and reduced weighted average interest rates (6.23% on term loans vs. 8.26% prior year).
- Cash Flow: Operating cash flow decreased to $17.6 million for the six months ended June 2001 from $21.5 million in the prior year, primarily due to an increase in accounts receivable.
Outlook, Risks, and Unusual Items
- Acquisitions: On July 6, 2001, CONMED acquired the remaining assets of Imagyn Medical Technologies' minimally invasive surgical business for 1.3 million shares of common stock (valued at $33.9 million). Results will be included starting in Q3 2001. Management expects a nonrecurring charge of approximately $1.2 million in the second half of 2001 for transition costs.
- Real Estate: The company purchased the Largo, Florida property (previously leased by Linvatec subsidiary) for approximately $23.0 million, assuming existing debt and financing the remainder.
- Capital Structure: The company plans to enter a $50 million accounts receivable securitization facility in Q3 2001 to repay term loans. The revolving credit facility ($100 million) expires in December 2002 and is expected to be renegotiated.
- Risks: Forward-looking statements are subject to risks including general economic conditions, competition, regulatory actions, and patent litigation. Foreign operations face risks related to currency devaluation and expropriation.
- Accounting Changes: The company is assessing the impact of new FASB standards (SFAS 141 and 142) regarding business combinations and goodwill amortization, effective July 1, 2001, and January 1, 2002, respectively.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the July 2001 Imagyn acquisition in upcoming filings.
- Monitor the status of the $100 million revolving credit facility renegotiation due in December 2002.
- Confirm the impact of the new $50 million accounts receivable securitization facility on debt reduction.
- Track the $1.2 million nonrecurring transition charge expected in the second half of 2001.
- Review the impact of SFAS 142 adoption on future earnings, specifically regarding the cessation of goodwill amortization.